eGPA and local inflammation within the ENT area; Impact of Mepolizumab treatment on the nasal microbiome and local and systemic immune response in eosinophilic granulomatosis with polyangitis (eGPA)

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-508029-28-00

Acronym

NL83176.042.23

Enrollment

150

Registered

2024-02-02

Start date

2024-02-13

Completion date

Unknown

Last updated

2024-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Eosinophilic Granulomatosis with Polyangiitis (eGPA)

Brief summary

The effect mepolizumab treatment has on the nasal microbiome profiles after three months of treatment

Interventions

DRUGMEPOLIZUMAB

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
The effect mepolizumab treatment has on the nasal microbiome profiles after three months of treatment	—

Countries

Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026